CNS Pharmaceuticals (NASDAQ:CNSP – Get Rating) and LumiraDx (NASDAQ:LMDX – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CNS Pharmaceuticals and LumiraDx, as provided by MarketBeat.com.

CNS Pharmaceuticals presently has a consensus target price of $30.00, indicating a potential upside of 1,104.82%. LumiraDx has a consensus target price of $7.17, indicating a potential upside of 637.99%. Given CNS Pharmaceuticals' higher probable upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than LumiraDx.

Risk and Volatility

Insider and Institutional Ownership

3.0% of CNS Pharmaceuticals shares are held by institutional investors. 8.6% of CNS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares CNS Pharmaceuticals and LumiraDx's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares CNS Pharmaceuticals and LumiraDx's gross revenue, earnings per share (EPS) and valuation.

CNS Pharmaceuticals has higher earnings, but lower revenue than LumiraDx. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than LumiraDx, indicating that it is currently the more affordable of the two stocks.

Summary

CNS Pharmaceuticals beats LumiraDx on 8 of the 13 factors compared between the two stocks.

About CNS Pharmaceuticals

(Get Rating)

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

About LumiraDx

(Get Rating)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.